Found: 3
Select item for more details and to access through your institution.
Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4203, doi. 10.1111/dom.15738
- By:
- Publication type:
- Article
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 7, p. 1865, doi. 10.1111/dom.15046
- By:
- Publication type:
- Article
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
- Published in:
- Diabetes & Metabolism Journal, 2023, v. 47, n. 6, p. 796, doi. 10.4093/dmj.2022.0315
- By:
- Publication type:
- Article